Kooperativer Bibliotheksverbund

UID:

Format: 1 Online-Ressource (XIV, 650 Seiten) : , Illustrationen.

ISBN: 978-3-030-91650-3

Series Statement: Fungal Biology

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-91649-7

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-91651-0

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-91652-7

Language: English

Subjects: Agriculture, Forestry, Horticulture, Fishery, Domestic Science , Biology

DOI: 10.1007/978-3-030-91650-3

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 Online-Ressource (XIX, 680 Seiten) : , Illustrationen.

ISBN: 978-981-1919-46-6

In: Role of microorganisms in pathogenesis and management of autoimmune diseases.

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1919-45-9

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1919-47-3

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1919-48-0

Language: English

DOI: 10.1007/978-981-19-1946-6

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 Online-Ressource (XIV, 650 Seiten) : , Illustrationen.

ISBN: 978-3-030-91650-3

Series Statement: Fungal Biology

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-91649-7

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-91651-0

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-91652-7

Language: English

Subjects: Agriculture, Forestry, Horticulture, Fishery, Domestic Science , Biology

DOI: 10.1007/978-3-030-91650-3

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 Online-Ressource (XIX, 680 Seiten) : , Illustrationen.

ISBN: 978-981-1919-46-6

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1919-45-9

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1919-47-3

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1919-48-0

Language: English

DOI: 10.1007/978-981-19-1946-6

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 Online-Ressource (XIX, 680 Seiten) : , Illustrationen.

ISBN: 978-981-1919-46-6

In: Role of microorganisms in pathogenesis and management of autoimmune diseases.

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1919-45-9

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1919-47-3

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1919-48-0

Language: English

DOI: 10.1007/978-981-19-1946-6

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Language: English

Author information: Shoenfeld, Yehuda 1948-

UID:

Language: English

Author information: Shoenfeld, Yehuda 1948-

UID:

Format: 1 Online-Ressource (XIV, 650 Seiten) : , Illustrationen.

ISBN: 978-3-030-91650-3

Series Statement: Fungal Biology

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-91649-7

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-91651-0

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-91652-7

Language: English

Subjects: Agriculture, Forestry, Horticulture, Fishery, Domestic Science , Biology

DOI: 10.1007/978-3-030-91650-3

URL: Volltext  (URL des Erstveröffentlichers)

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 online resource (984 pages)

Edition: 1st ed.

ISBN: 9780443139482

Note: Front Cover -- Regulatory T Cells and Autoimmune Diseases -- Copyright Page -- Contents -- List of contributors -- Foreword -- I. Regulatory T cells and immune system -- 1 Regulatory T cells and their functions in immune system -- 1.1 Introduction -- 1.1.1 Regulatory T cells -- 1.1.2 Establishment of immune homeostasis by the immune-regulatory cells -- 1.1.3 Crosstalk between regulatory T cells and the immune system -- 1.2 Types of Tregs and their origin -- 1.2.1 Thymus-derived or natural Treg (tTreg or nTreg) -- 1.2.2 Inducible or peripheral Tregs (iTregs or pTregs) -- 1.2.3 Type 1 regulatory T cells -- 1.2.4 Th3 cells -- 1.2.5 iTr35 cells -- 1.2.6 CD8+ regulatory T cells -- 1.3 Mechanism of action of Tregs -- 1.3.1 Secretion of inhibitory cytokines -- 1.3.2 Starving T cells of IL-2 -- 1.3.3 Expression of the inhibitory receptors -- 1.3.4 Direct cytotoxic effects -- 1.3.5 Metabolic regulation -- 1.4 Functional aspects of Tregs -- 1.4.1 Immune response suppression -- 1.4.2 Regulation of the disease-induced inflammation -- 1.4.3 Maintenance of self-tolerance -- 1.4.4 Tissue-specific regulation -- 1.4.5 Tregs' plasticity -- 1.5 Therapeutic role of Tregs in autoimmune diseases -- 1.6 Conclusion -- Acknowledgments -- Conflict of Interest -- References -- 2 Regulatory T cells: mechanisms of action -- 2.1 Introduction -- 2.2 Regulatory T cells -- 2.2.1 Natural Treg cells -- 2.2.2 Acquired Treg cells -- 2.3 Mechanisms of action of Treg cells -- 2.3.1 Suppression via inhibitory cytokines -- 2.3.2 Suppression by cytolysis -- 2.3.3 Suppression via cell-to-cell contact -- 2.3.4 Suppression by competition for growth factors -- 2.3.5 Suppression by disruption of metabolism -- 2.4 Mechanism of Treg cells in cancer -- 2.5 Mechanism of Treg cells in autoimmunity -- 2.6 Mechanism of Treg cells in infectious diseases -- 2.7 Conclusion -- Conflict of interest. , References -- 3 Regulatory T cells and autoimmunity -- 3.1 Introduction -- 3.1.1 What are regulatory T cells? -- 3.1.2 Tregs and cell phenotype plasticity -- 3.1.3 Tregs suppress immune cellular functions as well as allergic reactions -- 3.2 Regulatory T cells and inflammatory autoimmune diseases -- 3.2.1 Rheumatoid arthritis -- 3.2.2 Juvenile idiopathic arthritis -- 3.2.3 Systemic lupus erythematosus -- 3.2.4 Multiple sclerosis -- 3.2.5 Ankylosing spondylitis and inflammatory bowel disease -- 3.2.6 Scleroderma -- 3.2.7 Psoriasis and psoriatic arthritis -- 3.2.8 Primary Sjogren's syndrome -- 3.2.9 Type 1 diabetes -- 3.2.10 Pemphigus vulgaris -- 3.3 Therapeutic modulation of regulatory T cells as a therapy -- 3.4 Conclusion -- Conflict of Interest -- Disclosure Statement -- References -- Further reading -- 4 Sex differences in regulatory T cells during autoimmune disease -- Abbreviations -- 4.1 Regulatory T cells: the basics -- 4.2 T helper Tregs -- 4.3 Tregs and autoimmune disease -- 4.4 Autoimmune disease mechanisms -- 4.5 Sex differences in autoimmune disease -- 4.6 Sex differences in Tregs and autoimmune disease -- 4.7 Conclusions -- Conflict of interest -- Funding -- References -- II. Role of regulatory T cells in rheumatic diseases -- 5 Role of regulatory T cells in pathogenesis and therapeutics of systemic lupus erythematosus -- 5.1 Introduction -- 5.2 Regulatory T cells -- 5.3 Implications of regulatory T cells in SLE -- 5.3.1 Frequency, imbalance, and activity disturbance -- 5.3.2 Emerging regulatory T cells subsets -- 5.3.3 Ontogenesis of regulatory T cells' dysfunctionality -- 5.4 Clinical and experimental therapeutic strategies targeting regulatory T cells -- 5.5 Conclusions -- Conflict of interest -- References -- 6 Role of regulatory T cells in the pathogenesis and therapeutics of primary Sjögren's syndrome -- 6.1 Introduction. , 6.1.1 Historical overview -- 6.1.2 Prevalence and clinical manifestations -- 6.2 Diagnosis versus classification criteria -- 6.3 Physiopathology of pSS -- 6.4 Regulatory T cells and other T cell subsets in pSS -- 6.4.1 Treg and three types of Th cells -- 6.4.2 Treg and CD8+ T cells -- 6.4.3 The role of Treg cells in pSS -- 6.5 Treg cells in the treatment of pSS -- 6.5.1 Current therapies for pSS -- 6.5.2 Outcome of Treg cells in the pSS treatment -- 6.6 Target Treg cells in the pSS -- 6.6.1 Direct Treg targeting strategies -- 6.6.1.1 Treg-based cell therapy -- 6.6.1.2 Gene therapy -- 6.6.1.3 mTOR inhibitor -- 6.6.2 Indirect Treg targeting strategies -- 6.6.2.1 IL-10+ Breg cells -- 6.6.2.2 Agonists of aryl hydrocarbon receptor -- 6.6.2.3 Antiinflammatory cytokines supplementation -- 6.6.2.4 Gut microbiomes -- 6.6.3 Alternatives therapies -- 6.7 Conclusion -- Conflict of Interest -- References -- 7 Role of regulatory T cells in pathogenesis and therapeutics of rheumatoid arthritis and juvenile idiopathic arthritis -- 7.1 Introduction -- 7.1.1 Overview of the pathogenesis of RA -- 7.1.2 Overview of the pathogenesis of JIA -- 7.2 Immunosuppressive mechanisms of Treg cells in autoimmunity -- 7.3 Treg cell alterations in RA/JIA pathogenesis -- 7.3.1 Treg cell number in RA/JIA -- 7.3.2 Treg cell function in RA/JIA -- 7.4 Therapeutic potential of Treg cells in RA/JIA -- 7.4.1 Low dose of IL-2 -- 7.4.2 Other strategies that improve Treg cell function -- 7.4.2.1 Anti-TNF therapy -- 7.4.2.2 Anti-IL-6 therapy -- 7.4.2.3 Other therapies -- 7.4.2.3.1 CTLA4-Ig -- 7.4.2.3.2 Anti-IL-17 antibody therapy -- 7.4.3 Adoptive transfer of Treg cells -- 7.4.3.1 CAR-Treg cells -- 7.4.3.2 TCR-engineered Treg cells -- 7.5 Challenges of Treg-based therapies -- 7.5.1 Limited source of available Treg cells -- 7.5.2 Instability of Treg cells -- 7.6 Conclusion -- Funding. , Conflict of Interest -- References -- 8 Role of regulatory T cells in pathogenesis and therapeutics of psoriatic arthritis -- 8.1 Regulatory T cells -- 8.2 Psoriatic arthritis -- 8.2.1 Regulatory cells in psoriatic arthritis -- 8.2.1.1 Tregs in peripheral blood -- 8.2.1.2 Tregs in arthritic joints -- 8.2.1.3 Tregs in skin lesions -- 8.3 Regulatory T cells in the treatment of psoriatic arthritis -- 8.4 Concluding remarks -- Acknowledgment -- Conflict of interest -- References -- 9 Role of regulatory T cells in pathogenesis and therapeutics of spondyloarthritis -- 9.1 Introduction -- 9.2 Is the TREG's heterogeneity relevant to SpA? -- 9.3 SpA-specific impairment of negative immune regulation by Tregs -- 9.3.1 The role of LAG-3 and Tim-3 receptors -- 9.3.2 The role of the TIGIT receptor -- 9.3.3 The role of PD-1 -- 9.4 TREG's and intestinal inflammation in SpA -- 9.5 The strategies to promote the number and function of endogenous Tregs in SpA -- 9.5.1 Anti-TNF-α therapy (TNFi) and Tregs in SpA (infliximab, adalimumab, etanercept) -- 9.5.2 Anti-IL-17A/F therapy and TREGS in SpA (Secukinumab, ixekizumab, brodalumab) -- 9.5.3 IL-10/IL-27 induction and TREGS in SpA (butyrate, probiotics) -- 9.5.4 The JAK/STAT inhibitors and TREGS in SpA (Tofacitinib and Upadacitinib) -- 9.5.5 Mesenchymal stem cell infusion and Tregs in SpA -- 9.5.6 mTOR/AMPK pathway, Tregs, and SpA -- 9.5.7 PPAR-γ pathway, Tregs, and SpA -- 9.6 Conclusions and future directions -- Conflict of Interest -- References -- 10 Role of regulatory T cells in pathogenesis and therapeutics of ankylosing spondylitis -- 10.1 Introduction -- 10.2 Tregs subset and gene signature -- 10.3 The genetic bases of Treg dysfunction in ankylosing spondylitis -- 10.4 Pathogenic Tregs module in inflammatory rheumatic diseases -- 10.5 Tregs in synovial fluid and peripheral blood: similarities and differences. , 10.6 New technologies in studying Tregs -- 10.7 Tregs and treatment for ankylosing spondylitis -- 10.8 Conclusions and future therapeutic perspectives -- Conflict of Interest -- References -- III. Role of regulatory T cells in central nervous system demyelinating autoimmune diseases -- 11 Role of regulatory T cells in pathogenesis and therapeutics of multiple sclerosis -- Abbreviations -- 11.1 Introduction -- 11.2 Role of regulatory T cells in pathogenesis of multiple sclerosis -- 11.2.1 Altered Treg phenotype in MS -- 11.2.1.1 Results from animal studies confirmed important role of Tregs in MS -- 11.2.1.2 Characteristic of Tregs alterations in MS patients -- 11.3 Regulatory T cells as a target in MS therapy -- 11.3.1 Strategies for improving functions of Treg cells -- 11.3.2 Strategies leading to Treg cell induction for MS treatment -- 11.3.2.1 Induction of tolerogenic T-cells with immune peptides -- 11.3.2.2 Induction of tolerogenic response with bifunctional peptide inhibitors -- 11.3.2.3 Actions modifying the biology of dendritic cells -- 11.3.2.4 Nanoparticles -- 11.4 Conclusion -- Conflict of interest -- References -- 12 Role of regulatory T cells in the pathogenesis and therapeutics of neuromyelitis optica spectrum disorder -- List of abbreviations -- 12.1 Introduction -- 12.2 Neuromyelitis optica spectrum disorder: a rare disease -- 12.3 Clinical features of neuromyelitis optica spectrum disorder -- 12.4 Humoral mechanisms in pathogenesis of neuromyelitis optica spectrum disorder -- 12.5 Regulatory T cells in maintaining self-tolerance -- 12.6 Role of regulatory T cells in neuromyelitis optica spectrum disorder -- 12.7 Recently approved therapies to treat neuromyelitis optica spectrum disorder -- 12.8 Potential of B-cell maturation antigen, chimeric antigen receptor-T cells to treat neuromyelitis optica spectrum disorder. , 12.9 Potential of regulatory T cells to treat neuromyelitis optica spectrum disorder.

Additional Edition: Print version: Dwivedi, Mitesh Kumar Regulatory T Cells and Autoimmune Diseases San Diego : Elsevier Science & Technology,c2024 ISBN 9780443139475

Language: English

UID:

Format: 1 online resource (XIV, 272 p. 32 illus., 24 illus. in color.)

Edition: 1st ed. 2023.

ISBN: 1-0716-2827-5

Series Statement: Springer Protocols Handbooks,

Content: This volume provides basic insight and protocols relating to endophytic microbes. Chapter are divided into five major sections detailing basic isolation, bioactive metabolites production. endophytism, isolation and identification of endophytes, bioactive potentials, and screening of metabolites. Authoritative and cutting-edge, Endophytic Microbes: Isolation, Identification, and Bioactive Potentials aims to provide comprehensive and accessible methods to undergraduate, graduate, and established scientist.

Note: Isolation of endophytic bacteria from leaves, stems or roots -- Heat-treatment Method for Isolation of Bacillus spp. from Plant Tissues -- Isolation and detection of endophytic Streptomyces from Actinorhizal Casuarina root nodules -- Isolation of endophytic fungi from stems, leaves or roots -- Detection of endophytes by Cultivation method -- Detection of Endophytes by Visualization Methods -- Detection of endophytes by Immunological methods -- Detection of Endophytes by Electron Microscope -- Detection of Endophytes by Reactive Oxygen Staining -- Detection of Endophytes by Electron Microscope -- Identification of fungal endophytes by ITS rDNA technique -- Identification of Fungal Endophytes by 28srDNATechnique -- Detection of endophytes by molecular fingerprinting techniques -- Metagenomics and Pyrosequencing Approach -- Cultivation-based studies of endophytic fungi in plants -- Microscopy Based Studies -- Surrogate host test -- Hood and Shew staining -- Screening of endophytes for plant growth promoting metabolites -- Screening of endophytes for biocontrol properties -- Screening of Endophytes for Biocatalytic Tools -- Screening of Endophytes for Biosurfactant Production -- Screening of Endophytes for Antibacterial Properties -- Screening of endophytes for Nematicidal activities -- Screening of Endophytes for Virucidal Activity -- Screening of Endophytes for Fungicidal Activities -- Screening of endophytes for anti-cancer compounds.

Additional Edition: ISBN 1-0716-2826-7

Language: English

Keywords: Llibres electrònics ; Llibres electrònics

DOI: 10.1007/978-1-0716-2827-0